Zydus Lifesciences' consolidated revenue from operations grew 17% year-on-year to ₹6,123.2 crore, while net profit grew 38% ...

Sun Pharma’s Q2 revenue rose as innovative US drug sales exceeded generics. Domestic growth remained strong with new launches ...

The company’s total revenue from operations in Q2FY26 increased nearly 9% to ₹14,478.31 crore from ₹13,291.39 crore, ...

Teva Pharmaceutical Industries is able to absorb any potential tariffs imposed by the Trump administration, the company said ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

Bristol Myers Squibb raises 2025 revenue and EPS guidance on Q3 earnings beat, driven by strong Eliquis and Opdivo sales.

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal ...

For the third quarter, Bristol Myers posted revenue of $12.22 billion, beating analysts' average estimate of $11.8 billion, according to data compiled by LSEG. On an adjusted basis, the company earned ...

Additionally, in the U.S., MONJUVI® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with ...

The reporting duo demonstrate how drugmakers exploit public funding and legal loopholes to turn high profits, while justifying the price tag.

Dr. Reddy’s Laboratories is a buy, with key growth in biosimilars and GLP-1 segments. Click here to read my most recent ...

Bristol-Myers Squibb Company (NYSE: BMY) is set to report its third-quarter 2025 earnings on Thursday, October 30, before the market opens. Wall Street expects earnings per share of $1.52, down 15.6% ...